Tackling metabolic disorders with non-coding RNAs

Resalis Therapeutics' transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease.

2018 **Researcher at Harvard Medical School discover the role of miR-22 in metabolism control**

2021 **Resalis is founded with 10M € seed from trusted investors**

6.3M € 2.8M € 0.8M €

CLARIS VENTURES · 15 Anni 2007-2022 · Italian Angels for Growth · CLUB degli INVESTITORI

Leadership

Alessandro Toniolo
Chief Executive Officer

Riccardo Panella
CSO & Founder

Sakari Kauppinen
CTO & Founder

Board of Directors

Pietro Puglisi *(Chairman)*, Michael Hodges, Antonio Leone



RES-010 is a miR-22 inhibitor based on LNA chemistry and a mix-mer design to optimize stability and reduce toxicity.

2022 **Resalis' academic and non-academic collaborations reveal more details on RES-010 MoA including the additive effect on GLP-1 RA therapy**







Trend of >20% weight loss responders



inSphero · CENTER FOR RNA MEDICINE · gubra · omiics · Università di Torino MBC

2023 **Resalis successfully moved to NHP and started working with world class CRO to prepare for clinical development**

2024 **IND/CTA filing and Phase 1 execution**

ICON · evotec

2028 **Multiple exit options**